
icon
-
StorySatellite site - Automatic push and manual pull - EN - Root
-
Story
Satellite site - Automatic push and manual pull - no image - root
-
StorySatellite site - Automatic push and manual pull - Story Root
-
Press Release
Novartis ranks first in 2024 Access to Medicine Index
-
StoryNegative impact of the IRA on patient access to innovative treatments
-
StoryA partnership against epilepsy
-
StoryBeacon of Hope lights the way for a more equitable future
-
Press Release
Sandoz completes acquisition of leading antifungal agent Mycamine® from Astellas, reinforcing leading global anti-infectives portfolio
-
Press Release
Sandoz receives FDA approval for Tyruko® (natalizumab-sztn), first and only FDA-approved biosimilar for relapsing forms of multiple sclerosis
-
Press Release
Novartis publie l’invitation à l’AGE et la brochure d’information aux actionnaires. Sandoz publie le prospectus de cotation avant le vote sur la proposition de scission
-
Press Release
Novartis issues EGM Invitation and Shareholder Information Brochure. Sandoz publishes Listing Prospectus ahead of proposed Spin-off vote
-
Press Release
Novartis publiziert Einladung und Aktionärsbroschüre zur ausserordentlichen Generalversammlung. Sandoz veröffentlicht den Kotierungsprospekt im Vorfeld der Abstimmung zum vorgeschlagenen Spin-off
Pagination
- ‹ Previous page
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- …
- 10
- › Next page